–
A comparison with published averages, not a prediction. Trial people also had diet and activity support. This is not medical advice.
The trial results
| Trial | Dose | Average change |
|---|---|---|
| SURMOUNT-1, week 72 | Tirzepatide 5 mg | −15.0% |
| SURMOUNT-1, week 72 | Tirzepatide 10 mg | −19.5% |
| SURMOUNT-1, week 72 | Tirzepatide 15 mg | −20.9% |
| STEP 1, week 68 | Semaglutide 2.4 mg | −14.9% |
On placebo, the averages were −3.1% in SURMOUNT-1 and −2.4% in STEP 1. Both trials enrolled adults with obesity or overweight, without diabetes.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM, 2022.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM, 2021.
In the app
Reko charts your own weight beside your doses, so you can see your real curve.